An important role of CDK inhibitor p18INK4c in modulating antigen receptor-mediated T cell proliferation

Journal of Immunology

Volumn 167, Issue 6, 2001, Pages 3285-3292

  Kovalev, G I ^a   Franklin, D S ^a   Coffield, V M ^a   Xiong, Y ^a   Su, L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN P18; RAPAMYCIN; REGULATOR PROTEIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CYCLE G1 PHASE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA;

EID: 0035884934     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.6.3285     Document Type: Article

References (65)

1. 2-, calcineurin, and NF-AT
2. The dynamics of T cell receptor signaling: Complex orchestration and the key roles of tempo and cooperation
3. CD28/B7 system of T cell costimulation
4. Costimulatory regulation of T cell function
5. Signalling into the T-cell nucleus: NFAT regulation
6. Ligation of the T cell co-stimulatory receptor CD28 activates the serine-threonine protein kinase protein kinase B
7. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not Th2 cytokines
8. Upstream-downstream: CD28 cosignaling pathways and T cell function
9. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy
10. Symmetry of the activation of cyclin-dependent kinases in mitogen and growth factor-stimulated T lymphocytes
11. Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C
12. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells
13. Kip1 expression in human peripheral T lymphocytes
14. Cancer cell cycles
15. Principles of CDK regulation
16. The retinoblastoma protein and cell cycle control
17. 1-phase progression
18. 0 T cells
19. Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation
20. cdk4, during cell cycle entry and progression in normal human T lymphocytes
21. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes
22. 1 phase in primary human T lymphocytes
23. KIP1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
24. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors
25. Cip1 in muscle and other terminally differentiating cells
26. CIP1 CDK inhibitor family, is a candidate tumor suppressor gene
27. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development
28. Kip1 a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
29. 1 cyclin-Cdk proteins kinase activity, is related to p21
30. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes
31. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
32. Kip1-deficient mice
33. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors
34. Kip1
35. Kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
36. INK4a tumor suppressor versus other INK4 family members during mouse development and aging
37. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
38. ink4
39. Novel INK4 proteins, p19 and p18, are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6
40. INK4d, a p16-related inhibitor specific to CDK6 and CDK4
41. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
42. INK4c in tumor-derived cell lines and primary tumors
43. INK4c cell cycle inhibitors in proliferation and tumorigenesis
44. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes
45. INK4d-deficient mice are fertile despite testicular atrophy
46. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis
47. Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: Efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro
48. Itk negatively regulates induction of T cell proliferation by CD28 costimulation
49. INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation
50. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity
51. Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6
52. 1 phase and cell cycle regulation by TGF-β
53. 1 checkpoint control
54. Kip1 results in increased apoptosis and delayed differentiation during mouse development
55. The mechanism of action of cyclosporin A and FK506
56. 1/S transition
57. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
58. 1 cyclin-dependent kinases
59. Why are there so many CDK inhibitors?
60. Regulation of synthesis and activity of the PLSTIRE protein (cyclin-dependent kinase 6 (cdk6)), a major cyclin D-associated cdk4 homologue in normal human T lymphocytes
61. 1 kinase activity for cdk6, a novel cyclin D. partner
62. The interleukin-4 receptor activates STAT5 by a mechanism that relies upon common γ-chain
63. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells
64. INK4- and p18-containing complexes in human cell lines
65. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors